Sept 28 AI news briefing: all three stories below were confirmed by official sources or first-tier media within the last 24 hours — NVIDIA's Open Agent Safety Platform, China potentially clearing NVIDIA workstation chip purchases, and MIT using AI to make RNA vaccines stable at room temperature for a year.
NVIDIA launches Open Agent Safety Platform, with a hardware watchdog that isolates rogue agents in real time
On Sept 28, NVIDIA launched the Open Agent Safety Platform; its official press release says more than 100 organizations are already using the underlying technology. The platform has two layers: OpenShell, an open-source (Apache 2.0) secure runtime that sandboxes every agent and enforces file, network, tool, and credential access policies; and Sentry, a hardware watchdog running on the BlueField-4 DPU — invisible and unreachable to agents, able to isolate a rogue agent in milliseconds.
Why it matters: agent safety is shifting from "model self-restraint" to "independent external enforcement." Open source at the software layer, hard isolation at the silicon layer — NVIDIA is making a play for agent infrastructure leadership. Backing from Anthropic, Microsoft, Hugging Face and others gives it a shot at becoming the de facto standard. One caveat: OpenShell itself shipped back in March; the news today is the platform launch as a whole plus the Sentry reference design — don't write this up as an OpenShell debut.
Beijing may clear ByteDance, Alibaba to buy NVIDIA's new workstation chips
The Information reported on Sept 27 (picked up the same day by Reuters) that China's Ministry of Industry and Information Technology has asked companies including ByteDance and Alibaba to report plans to buy NVIDIA's new chips, signaling to some that approvals may be coming. The chip in question is the RTX PRO 5500 — a Blackwell-generation, 84GB GDDR7 high-end workstation GPU that some in the industry believe could sidestep US export controls.
How to read this signal: the strained US–China AI chip supply chain shows signs of loosening. But two caveats: Reuters explicitly flagged that it could not independently verify the report; and the "one million units" figure circulating on social media was not confirmed by Reuters — don't treat it as fact. This is an approval signal, not an approval.
MIT uses AI to reformulate RNA vaccines, stable at room temperature for a year
MIT News reported on Sept 28 on a study published in Nature Biotechnology. The MIT team, working with CSAIL, used a data-efficient machine-learning algorithm to predict the optimal excipient mix out of nearly 50 FDA-approved options — a few rounds of "predict–test–feed back" took weeks, replacing exhaustive screening that used to take months. A COVID mRNA vaccine in the new formulation stays stable at room temperature for up to a year, or two months at 37°C; mouse trials showed immune responses equivalent to Moderna's original formulation. The same algorithm also adapted a Pfizer-like formulation and was turned into a microneedle patch.
Where the impact lands: ultra-cold storage (-20 to -80°C) is the biggest bottleneck to getting RNA vaccines into developing countries. A year of room-temperature stability would slash cold-chain costs, and the microneedle patch opens a path to painless, at-home vaccination.
